Assuming that CAIX is a tumour-specific protein that is released into the circulation as a direct response to therapy [11], i.e., that no other tissue of origin contributes as a toxic response to the given therapy, the absolute change in serum CAIX level might be utilised in risk-adapted individualisation of LARC treatment. This evidence concerns the gene CA9 and neoplasm.